Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1970 Jun;49(6):1114–1121. doi: 10.1172/JCI106327

Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma

Sydney E Salmon 1, Beth A Smith 1
PMCID: PMC322579  PMID: 4987170

Abstract

Studies of synthesis of IgG paraproteins were performed in 10 patients who had IgG myeloma in order to quantitate cellular immunosynthetic functions and derive estimates of the number of tumor cells present in such patients. Serial in vitro studies demonstrated constancy in the cellular rate of IgG paraprotein secretion for up to 8 months. Average molecular synthesis rates in different patients ranged from 12,500 to 85,000 molecules of IgG per minute per myeloma cell. Estimated total body tumor cell number ranged from 0.5 × 1012 to 3.1 × 1012 myeloma cells, and could be correlated with the degree of skeletal damage observed on roentgenograms (P = <0.01). Serial measurements of tumor cell number may prove useful in characterizing the growth rate and natural history of multiple myeloma. Myeloma is the first metastatic human malignancy in which quantitative measurements of the body's burden of malignant cells have been obtained.

Full text

PDF
1114

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALPER C. A., FREEMAN T., WALDENSTROEM J. THE METABOLISM OF GAMMA GLOBULINS IN MYELOMA AND ALLIED CONDITIONS. J Clin Invest. 1963 Dec;42:1858–1868. doi: 10.1172/JCI104870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alexanian R., Bergsagel D. E., Migliore P. J., Vaughn W. K., Howe C. D. Melphalan therapy for plasma cell myeloma. Blood. 1968 Jan;31(1):1–10. [PubMed] [Google Scholar]
  3. BERSON S. A., YALOW R. S., SCHREIBER S. S., POST J. Tracer experiments with I131 labeled human serum albumin: distribution and degradation studies. J Clin Invest. 1953 Aug;32(8):746–768. doi: 10.1172/JCI102789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DE BERGSAGEL D. E., MIGLIORE P. J., GRIFFITH K. M. MYELOMA PROTEINS AND THE CLINICAL RESPONSE TO MELPHALAN THERAPY. Science. 1965 Apr 16;148(3668):376–377. doi: 10.1126/science.148.3668.376. [DOI] [PubMed] [Google Scholar]
  5. Edwards G. A., Zawadzki Z. A. Extraosseous lesions in plasma cell myeloma. A report of six cases. Am J Med. 1967 Aug;43(2):194–205. doi: 10.1016/0002-9343(67)90164-7. [DOI] [PubMed] [Google Scholar]
  6. FAHEY J. L., HORBETT A. P. Human gamma globulin fractionation on anion exchange cellulose columns. J Biol Chem. 1959 Oct;234:2645–2651. [PubMed] [Google Scholar]
  7. Frei E., 3rd, Freireich E. J. Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother. 1965;2:269–298. doi: 10.1016/b978-1-4831-9930-6.50011-3. [DOI] [PubMed] [Google Scholar]
  8. Griswold D. P., Jr, Schabel F. M., Jr, Wilcox W. S., Simpson-Herren L., Skipper H. E. Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster. Cancer Chemother Rep. 1968 Apr;52(3):345–387. [PubMed] [Google Scholar]
  9. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  10. Hobbs J. R. Growth rates and responses to treatment in human myelomatosis. Br J Haematol. 1969 Jun;16(6):607–617. doi: 10.1111/j.1365-2141.1969.tb00441.x. [DOI] [PubMed] [Google Scholar]
  11. LAIRD A. K. DYNAMICS OF TUMOR GROWTH. Br J Cancer. 1964 Sep;13:490–502. doi: 10.1038/bjc.1964.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. NATHANS D., FAHEY J. L., POTTER M. The formation of myeloma protein by a mouse plasma cell tumor. J Exp Med. 1958 Jul 1;108(1):121–130. doi: 10.1084/jem.108.1.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. NOSSAL G. J., MAKELA O. Elaboration of antibodies by single cells. Annu Rev Microbiol. 1962;16:53–74. doi: 10.1146/annurev.mi.16.100162.000413. [DOI] [PubMed] [Google Scholar]
  14. OSGOOD E. E. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep. 1960 Nov;9:1–10. [PubMed] [Google Scholar]
  15. OSSERMAN E. F., TAKATSUKI K. PLASMA CELL MYELOMA: GAMMA GLOBULIN SYNTHESIS AND STRUCTURE. A REVIEW OF BIOCHEMICAL AND CLINICAL DATA, WITH THE DESCRIPTION OF A NEWLY-RECOGNIZED AND RELATED SYNDROME, "H-GAMMA-2-CHAIN (FRANKLIN'S) DISEASE. Medicine (Baltimore) 1963 Nov;42:357–384. [PubMed] [Google Scholar]
  16. SKIPPER H. E., SCHABEL F. M., Jr, WILCOX W. S. EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. Cancer Chemother Rep. 1964 Feb;35:1–111. [PubMed] [Google Scholar]
  17. SOLOMON A., WALDMANN T. A., FAHEY J. L. Clinical and experimental metabolism of normal 6.6s gamma-globulin in normal subjects and in patients with macroglobulinemia and multiple myeloma. J Lab Clin Med. 1963 Jul;62:1–17. [PubMed] [Google Scholar]
  18. Salmon S. E., Mackey G., Fudenberg H. H. "Sandwich" solid phase radioimmunoassay for the quantitative deterimination of human immunoglobulins. J Immunol. 1969 Jul;103(1):129–137. [PubMed] [Google Scholar]
  19. Salmon S. E., Smith B. A. Sandwich solid phase radioimmunoassays for the characterization of human immunoglobulins synthesized in vitro. J Immunol. 1970 Mar;104(3):665–672. [PubMed] [Google Scholar]
  20. Strober W., Wochner R. D., Barlow M. H., McFarlin D. E., Waldmann T. A. Immunoglobulin metabolism in ataxia telangiectasia. J Clin Invest. 1968 Aug;47(8):1905–1915. doi: 10.1172/JCI105881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Waldmann T. A., Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1–110. doi: 10.1159/000385919. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES